摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-hydroxy-2-(4-sulfamoylpiperazin-1-yl)pyrimidine-5-carboxamide | 603991-93-1

中文名称
——
中文别名
——
英文名称
N-hydroxy-2-(4-sulfamoylpiperazin-1-yl)pyrimidine-5-carboxamide
英文别名
——
N-hydroxy-2-(4-sulfamoylpiperazin-1-yl)pyrimidine-5-carboxamide化学式
CAS
603991-93-1
化学式
C9H14N6O4S
mdl
——
分子量
302.314
InChiKey
KZBOEVJIHBIURW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.2
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    150
  • 氢给体数:
    3
  • 氢受体数:
    9

文献信息

  • INHIBITORS OF HISTONE DEACETYLASE
    申请人:VAN EMELEN Kristof
    公开号:US20100010004A1
    公开(公告)日:2010-01-14
    This invention comprises the novel compounds of formula (I) wherein n, R 1 , R 2 , R 3 , R 4 , Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.
  • Inhibitors Of Histone Deacetylase
    申请人:JANSSEN PHARMACEUTICA, N.V.
    公开号:US20130245034A1
    公开(公告)日:2013-09-19
    This invention comprises the novel compounds of formula (I) wherein n, R 1 , R 2 , R 3 , R 4 , Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.
  • COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS
    申请人:Larsson Pia
    公开号:US20140051716A1
    公开(公告)日:2014-02-20
    There is provided a compound which is a histone deacetylase (HDAC) inhibitor, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, for use in: (I) treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation; and/or (II) potentiating the degradation of fibrin deposits and preventing such deposits associated with pathological conditions or which may lead to such conditions, wherein the HDAC inhibitor, and the dose thereof, is as described in the description. There is also provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in improving or normalizing endogenous fibrinolysis impaired by local or systemic inflammation.
  • US7615553B2
    申请人:——
    公开号:US7615553B2
    公开(公告)日:2009-11-10
  • US8455498B2
    申请人:——
    公开号:US8455498B2
    公开(公告)日:2013-06-04
查看更多